Background. Patients with primary sclerosing cholangitis (PSC) may be at higher risk of malignancy after liver transplantation (LT) compared to other LT recipients. We aimed to determine the cumulative incidence of/risk factors for long-term cancerrelated mortality in patients with PSC after LT. Methods. All adult patients underwent LT for PSC without cholangiocarcinoma from 1984 to 2012, with follow-up through June 2015. We estimated cumulative incidence, risk factors, and mortality from de novo malignancies after LT. Results. Two hundred ninety-three patients were identified (mean [SD] age, 47 [12] years; 63.3% males; 2.4% smoking at LT). Over a median of 11.5 years (range, 6.4-18.6 years), 64 patients (21.8%) developed 73 nonskin cancers, including 46 solid-organ cancers (renal, 11; colorectal, 11; prostate, 7; breast, 5; pancreas, 5; ovarian/endometrial/ vulvar cancers, 3; and de novo cholangiocarcinoma, 4). Twenty-two patients developed hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin disease, 2; and myelodysplastic syndrome, 2). Five patients developed melanoma. The 1-, 5-, 10-, and 20-year cumulative incidences of cancer were 2.1%, 8.6%, 18.7%, and 27%, respectively. Mortality of patients with PSC who developed cancer was higher than that of patients with PSC without cancer (hazard ratio, 2.2; P < 0.01). On multivariate analysis, recipient's age and elevated pre-LT international normalized ratio were associated with increased risk of de novo (nonskin) malignancy. Conclusion. The 10-year cumulative risk of cancer after LT for advanced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal cancer, and renal cell cancer being the most common. Post-LT de novo nonskin cancer decreased overall posttransplant survival. Only recipient's age and elevated international normalized ratio at LT were associated with increased nonskin cancer risk.
L
iver transplant (LT) recipients are known to have an increased risk of developing de novo malignancies when compared to an age-matched general population. [1] [2] [3] [4] [5] [6] De novo cancer is an important leading cause of late death after LT. [7] [8] [9] [10] Previous studies have estimated that the incidence of de novo cancers after LT ranged from 2.6% to 21.7% 3, 4, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ; with variation based on the demographics of the transplant population, duration of follow-up, differences in indications for LT, immunosuppression regimens, and the era of transplantation. Malignancies associated with environmental factors such as viruses, alcohol use, and tobacco use are common after LT. [18] [19] [20] [21] [22] Other factors such as age of the recipient, history of cigarette smoking, alcoholic liver disease, primary sclerosing cholangitis (PSC), and duration and intensity of immunosuppression increased the overall risk of developing malignancies. 8, 9, [22] [23] [24] [25] Cancer is one of the leading causes of mortality in nontransplant patients with PSC. 26 The risk for hepatobiliary, colorectal, and pancreatic cancer is increased in patients with PSC owing to the presence of chronic inflammation. 26 Knowledge of how LT modifies cancer risk in patients with PSC is poor. In this study, we sought to examine the cumulative incidence of and risk factors for de novo malignancies in patients with PSC and their impact on long-term mortality after LT.
MATERIALS AND METHODS
The Mayo Clinic Institutional Review Board approved this study for patients who had consented to the use of their medical records for research.
Patients
Through a prospectively maintained solid-organ transplant registry, we identified 373 adult patients (>18 years) with PSC who underwent LT at Mayo Clinic Rochester between January 1984 and December 2012. From this cohort, we included patients with PSC, with or without associated inflammatory bowel disease (IBD), who underwent LT for advanced disease in our study. We excluded patients who underwent LT for cholangiocarcinoma, since these patients are inherently at higher risk of recurrent as well as de novo malignancy after LT.
Data on baseline demographics (age, sex, and race), clinical variables (prior malignancy, alcohol dependence, cigarette smoking status, comorbidities), transplant-related (allograft failure, type of donor, recurrent PSC, biliary strictures after LT, cytomegalovirus infection, Epstein-Barr virus [EBV] infection, cytomegalovirus mismatch, EBV mismatch, ABO blood type mismatch, sex mismatch, HLA mismatch, episodes of acute cellular rejection, chronic rejection, era of transplantation and retransplantation), associated IBD-related (subtype of IBD, IBD disease activity status at time and after LT, IBD treatment before and after transplant, and intact colon at time of LT), laboratory-related (electrolyte/renal function, liver function, and complete blood cell count with differential at time of LT) and immune suppression-related variables (use of mycophenolate mofetil, azathioprine, prednisone, tacrolimus-, cyclosporine-, and sirolimus-based regimen) were abstracted systematically. At our center, immunosuppression protocols varied from cyclosporine, prednisone, and azathioprine before 1995 to a gradual shift to tacrolimus, prednisone, and mycophenolate mofetil after 1995. Patients who developed biopsy-proven acute cellular rejection were treated with 3 intravenous boluses of methylprednisolone (1000 mg).
Outcomes
The primary outcome of our study was to estimate the cumulative incidence of all de novo cancers (excluding nonmelanoma skin cancers [NMSC]) in patients with PSC after LT, and the impact of these cancers on overall survival in these patients. Demographic, clinical, PSC-, transplant-, associated IBD, immunosuppression-, and laboratoryrelated risk factors associated with development of de novo malignancy after LT for PSC were identified.
Statistical Analysis
The data are reported as mean (SD), median (interquartile range [IQR]), and categorical variables by counts and percentages as appropriate. We recorded person-years at risk from the date of transplantation until the date of first cancer diagnosis (except NMSC), death, emigration or end of study period (June 30, 2015) for each individual in the cohort. We included only incident cancers occurring at least 30 days after LT to minimize the risk of detection bias and misclassification; patients with a history of cancer diagnosed before LT were still considered at risk of other organ cancers after LT. Cumulative incidence of and mortality from cancer was calculated using Kaplan-Meier survival analysis. To identify risk factors (present at time of LT) associated with development of cancer, we performed univariate time-to-event analysis using log-rank test. Variables which were significant (P < 0.10) on univariate analysis were then included in a multivariate Cox proportional hazard analysis to identify independent risk factors associated with malignancy. All statistical analyses were conducted using JMP version 10 for Windows (SAS Institute Inc., Cary, NC) and Easy R version 1.33. P < 0.05 was considered statistically significant. Easy R was used to calculate cumulative incidence of competing events.
RESULTS

Patient Eligibility and Demographics
Of 373 patients who underwent LT for PSC in the study period, 293 were included in the current analysis; 80 patients who underwent LT for cholangiocarcinoma were excluded. Sixty-four patients (21.8%) developed 73 malignancies (excluding NMSC) ( Figure 1 Types of de novo malignancies that developed after LT in patients with PSC are depicted in Table 2 . Renal and colorectal cancers were the most common solid-organ tumor, and PTLD was the most common hematologic malignancy. Table 3 demonstrates those with multiple de novo malignancies after LT. The cumulative incidence for de novo cancer (excluding NMSC) in PSC patients after LT was 2.1%, 8.6%, 18.7%, and 27% at 1, 5, 10 and 20 years, respectively (Figure 2) . PSC patients had a 1-, 5-, and 10-year probability for developing a hematologic malignancy of 0.3%, 3.4%, and 7.4%, respectively, compared to 0.3%, 3.4%, and 10.0% for developing a solid malignancy. The 10-year cumulative incidence of colorectal cancer in patients with an intact colon was 4.5% in patients with PSC. The 10-year cumulative incidence of colectomy for colonic dysplasia in patients with PSC-IBD was 25%.
Survival After LT With and Without De Novo Cancer
The median follow-up after orthotopic liver transplantation was 14.7 years (IQR, 9.0-20.9) for cases and 11.2 years (IQR, 6.2-18.0) for controls. Among the 30 patients in the cancer group who died, de novo malignancy was the cause of death in 22 patients (73.3%), followed by PSC recurrence in 3 patients (10%), infection in 2 patients (6.7%), and other causes in 3 patients (cardiac arrest, respiratory failure, and mechanical fall). In general, patients with renal cell carcinomas and prostate adenocarcinomas responded well to cancer treatment, but some patients developed a second cancer after treatment (Table 3 ). Approximately 1 of 2 of patients with colorectal cancer and all patients with pancreatic cancer died of metastatic disease.
The noncancer-related cumulative mortality rates were 2.1%, 8.6%, and 18.7% at 1, 5, and 10 years after OLT, respectively. The cancer-related cumulative mortality rates were 0.7%, 1.1%, and 4.9% at 1, 5, and 10 years after OLT, respectively ( Figure 3 ). The cumulative probability of cancer-related death after the diagnosis of any de novo cancer (excluding NMSC) was 16.7% at 1 year and 40.0% at 5 years. The cumulative probability of death after the 
Risk Factors Associated with Development of De Novo Malignancy
By univariate analysis, recipient age (per year) at time of LT (HR, 1.03; 95% CI, 1.004-1.052; P = 0.019), high neutrophil-to-lymphocyte ratio (NLR, >4.27) at time of LT (HR, 1.10; 95% CI, 1.01-1.18; P = 0.023), and elevated international normalized ratio (INR) at time of LT (HR, 1.09; 95% CI, 1.005-1.17; P = 0.039) were significant factors associated with de novo malignancy development. In a multivariate model that included age at LT, high INR, and high NLR, only recipient age at time of LT (HR per year, 1.05; 95% CI, 1.02-1.10; P < 0.01) and elevated INR at time of LT (HR, 1.12; 95% CI, 1.02-1.21; P = 0.02) were associated with increased risk. Inflammatory bowel disease status at time of and after LT, the presence or absence of colon, and the era of transplantation were not significantly associated with time to malignancy ( Table 4) .
Posttransplant Lymphoproliferative Disease After Liver Transplantation for Primary Sclerosing Cholangitis
Posttransplant lymphoproliferative diseases accounted for most (81.8%) of the hematologic malignancies, which developed after LT. The 1-, 5-, and 10-year cumulative incidences of PTLD were 0.7%, 2.9% and 6.0%, respectively.
Development of PTLD after LT was not associated with a decrease in survival (HR, 0.98; 95% CI, 0.36-2.68; P = 0.97). On univariate Cox proportional hazard analysis, leukopenia at time of LT (white blood cell count < 3.500 [17.8] years; 68.0% males; 1.6% smoking at time of LT) who had an intact colon at time of LT and were followed up for screening colonoscopy, 59 patients (46.1%) developed colorectal dysplasia of any type (39 developed low-grade dysplasia, 3 developed high-grade dysplasia, and 17 developed indefinite dysplasia) over a median follow-up of 7.8 years (IQR, 4.1-14.1) . The 1-, 5-, and 10-year cumulative incidence probabilities of colorectal dysplasia of any type were 5.5 %, 22.8%, and 36.9%, respectively. On univariate Cox proportional hazard analysis, male sex (HR, 1.8; 95% CI, 1.02-3.57; P = 0.04) was associated with increased risk of colonic dysplasia.
DISCUSSION
This study showed that de novo malignancy is a substantial cause of death in LT recipients with underlying PSC. Excluding NMSC, de novo cancer developed in 21.8% of the patients within 12 years of transplantation, and accounted for half of the deaths after LT. Posttransplant lymphoproliferative disease was the most commonly observed hematologic malignancy, whereas renal cell cancer and colorectal cancer were the most commonly observed solid tumors after LT for PSC. Although not a cohort with advanced age, recipient age was still associated with increased cancer risk. Surprisingly, elevated INR at the time of LT was also an independent risk for malignancy. This would likely reflect cirrhotic stage disease with liver failure as opposed to recurrent cholangitis as the indication for transplantation or could reflect qualitative changes in vitamin K-producing bacteria in the gut, but how this confers higher risk for de novo malignancy posttransplant is unclear.
The overall frequency of de novo cancer was high compared to previous studies including all liver transplant recipients, 3, 4, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] but this is somewhat expected, since we studied a patient cohort known to be higher risk of certain malignancies such as colorectal cancer and cholangiocarcinoma. Reported frequencies of cancer can also fluctuate depending on factors such as colectomy rates, given patients with PSC and associated IBD are at higher risk for colorectal cancer. 5, 11, 27 Furthermore, since patients with cholestatic liver disease have experienced the best long-term post-LT survival, these patients may have had longer follow-up time to develop malignancies compared to other transplant patients. 23 Our data found that the rates of graft failure were lower in the group of patients with cancer; this may be due to less time of being at risk for graft failure. On the other hand, patients with PSC are thought to be exposed to more intense immunosuppression therapy, with coexisting IBD possibly reducing graft rejection. 28 Unfortunately, we do not have detailed data on pretransplant IBD-related immunosuppression nor levels of immunosuppression posttransplant to evaluate this risk factor further.
High NLR is a biomarker for chronic inflammation, which can predispose the individual to malignancy and can affect the host immune response. 29 Although not an independent variable for all de novo malignancy in this study, further studies are needed to examine the prognostic use of NLR with transplant outcomes. The increased risk of PTLD in subjects with leukopenia may be related to decreased immune surveillance. Elevated INR at time of LT was also found to be a risk factor for de novo cancer. Coagulopathy reflects the deterioration of liver function, which results in immune dysfunction. 30 Coagulopathy leading to thrombosis can also represent the earliest clinical manifestation of an occult cancer. 31 Elevated INR could be caused by altered host-microbiota interactions and dysbiosis, which have tumor-promoting effects. 32 However, the mechanisms underlying this phenomenon and the true correlation between coagulopathy and future de novo malignancy remain unclear.
In this study, we found that PTLD was the most commonly reported de novo cancer after LT for PSC, which accounted for 24% of de novo cancers. Posttransplant lymphoproliferative disease is associated with EBV infection in 90% of the cases, especially in the case of EBV seronegative recipients of organs from EBV-seropositive donors. 33 The overall frequency of PTLD was 6.1% in all patients, which is higher than the reported frequency in the literature. 5, 9 This supports the previous finding by our group in a multicenter study showing that patients with PSC accounted for the highest fraction of hematologic malignancies after LT compared to other indications for LT. 8 This increased risk could be secondary to the potency and duration of immunosuppression, but other factors are likely at play. Further investigations into genetic and possibly pharmacogenomics of these patients are warranted. 34, 35 The presence of leukopenia at the time of LT reflects a more advanced stage of cirrhosis, since the occurrence of leukopenia lags thrombocytopenia by almost 2.5 years. Almost all of our leukopenic patients (97.2%) had thrombocytopenia at the time of LT, and this combination could predict increased morbidity and mortality. 36 The occurrence of PTLD in leukopenic patients could be attributed to an additional underlying immunodeficiency in such patients or to impaired cytokine release and activity. Further investigation is warranted.
Our study found that colorectal cancer and renal cell cancer were the most common solid tumors after LT for PSC. We confirmed the results of a study by the National Institute of Diabetes and Digestive and Kidney Diseases that most post-LT patients who developed colorectal cancer (10/11 patients) had ulcerative colitis (with intact colon at the time of LT). 8 The 10-year cumulative incidence of colorectal cancer in our population was lower than what was reported previously. 8, 37 This low rate could be attributed to the exclusion of patients with colonic dysplasia and due to frequent colonoscopic surveillance and early colectomy in selected patients with long-standing severe bowel disease.
The increased risk of renal cell cancer among liver transplant patients has been reported in previous studies. 38 The risk increased up to 30-fold after LT in 1 study. 23 Chronic kidney disease, smoking, overweight, and hypertension are known risk factors for renal cell cancer after solid-organ transplantation. 39, 40 In contrast to what was reported in the literature, patients with renal cell cancer had a good prognosis in our study. 2 This could be attributed to early detection on routine annual abdominal ultrasound performed per protocol.
Pancreatic cancer and de novo cholangiocarcinoma accounted for 8% and 5.4% of cancers, respectively. Pancreatic adenocarcinoma accounted for all of the pancreatic cancer cases, and all patients did poorly despite systemic treatment. One previous study found a significantly increased risk of pancreatic cancer after LT. 41 Similar to the general population, the 5-year relative survival rate for pancreatic cancer is low (8%) because more than 1 of 2 of patients are diagnosed at a distant late stage, which decreases the survival to 2%. 42 The retained intrapancreatic portion of the common bile duct is the likely source for the pancreatic cancers. Of note, all patients who developed pancreatic cancer were immunosuppressed with mycophenolate mofetil, prednisone, and tacrolimus; and none of them were exposed to azathioprine or cyclosporine. Whether such agents increased the risk or simply reflects a different era of transplant is difficult to determine, but this observation needs further evaluation in prospective studies. Notably, all patients with posttransplant cholangiocarcinoma had a hepaticojejunostomy and recurrent PSC, thus truly de novo bile duct cancer.
Common de novo solid tumors after LT such as head and neck, which accounts for 17.0% of the solid tumors after LT, esophageal cancer (12.0%), and lung cancer (10.0%) were not frequent in our study. 43 The risk of these cancers developing is inversely related to age and highly associated with excess alcohol consumption and cigarette smoking. 2, 25, 44, 45 The low proportion of smokers and the young age of patients in our study accounted for such results.
Intensive screening protocols were followed at our institution after LT for PSC. This was proved to promote early diagnosis and improved survival. 46 Most of renal, colon, and prostate cancers and some of the pancreatic, PTLD, and CCA were detected owing to adherence to such protocols. The strategies, which were followed, included annual dermatologic skin examination; annual abdominal ultrasound, chest, and abdominal CT scan annually for the first 3 years after transplant; annual prostate-specific antigen and digital rectal examination; mammography every year; colonoscopy every 5 years if no history of colonic dysplasia or IBD, every 3 to 5 years if with history of neoplasia or advanced adenomas, and yearly in patients with IBD. 43, 47 All of the aforementioned screening tests are performed before transplant to ensure the patient is cancer-free before transplant.
Whereas this is the only study that determines the cumulative incidence and risk factors for de novo malignancies after LT for patients with PSC, there are some limitations. In addition to the retrospective nature of our study, we were not able to report the intensity of immunosuppression in all patients owing to logistic reasons. In addition, other confounding factors may not have been accounted for. We follow transplant recipients for life with annual evaluations; thus, the capture rate of identified cancers is high in our medical record. However, it is possible that not all cancers in this population were accounted for.
In conclusion, de novo malignancy developed in 21.8% of patients with PSC after LT. The estimated 10-year cumulative risk for de novo cancer was 18.7%. The most common malignancies were PTLD, renal cell cancer, and colorectal cancer. Mortality relating to de novo malignancies was high. Adherence to screening protocols is recommended to detect malignancies in early stages to increase the probability of survival.
